Company intelligence / Profile preview

Selvion

Basel, Basel-Stadt, Switzerland

Ownership: Private
Development stage: Other

Overview

Selvion is a Swiss clinical-stage biotechnology company focused on developing innovative small molecule therapies for the treatment of cancer. The company's primary focus is on restoring the function of the p53 tumor suppressor protein by inhibiting the MDM2-p53 interaction. Its lead program, SEL-101, is designed to treat patients with p53 wild-type tumors across various solid and hematological indications. Selvion aims to address significant unmet needs in oncology through targeted therapies that trigger apoptosis in cancer cells while sparing healthy tissue.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Selvion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selvion.

Explore the full profile